rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Sujal Shah

Director

Company insider

Files Form 4 as: Director, Tvardi Therapeutics; Chief Executive Officer, CymaBay Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
92
Buys
13
Sells
3
Bought
$630K
Sold
$3.2M
Companies
2
Companies where not an officer
1
First trade
23 Dec 2013
Last trade
9 Jun 2026
Last filed
11 Jun 2026

Companies traded

Where they are an officer
CymaBay TherapeuticsDirector, Officer · last 22 Mar 202413 buys · 3 sells
Everywhere else they filed: board seats, 10% stakes, other companies
TVRD Tvardi TherapeuticsDirector · Biotechnology · last 9 Jun 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
9 Jun 2026filed 11 Jun 2026TVRD Tvardi Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—6,000 at $0.00filing
9 Jun 2026filed 11 Jun 2026TVRD Tvardi Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—6,000 at $0.00filing
17 Apr 2025filed 21 Apr 2025TVRD Tvardi Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—12,000 at $0.00filing
15 Apr 2025filed 17 Apr 2025TVRD Tvardi Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—10,394filing
15 Apr 2025filed 17 Apr 2025TVRD Tvardi Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—8,047filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—88,351filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—39,375filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—50,000filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—47,916filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—90,000filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—621,101filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—146,875filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—314,120filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—536,032filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—284,712filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—649,999filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—800,000filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—357,500filing
22 Mar 2024filed 22 Mar 2024CymaBay TherapeuticsSEC FORM 4 Code D—310,420filing
22 Mar 2024filed 22 Mar 2024CymaBay TherapeuticsSEC FORM 4 Code D—96,250filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed16

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.